Cargando…

Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

BACKGROUND: Many conventional chemotherapeutic drugs are known to be involved in DNA damage, thus ultimately leading to apoptosis of leukemic cells. However, they fail to completely eliminate leukemia stem cells (LSCs) due to their higher DNA repair capacity of cancer stem cells than that of bulk ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yin, Wang, Yan, Zhou, Yong, Li, Jie, Chen, Kai, Zhang, Leisi, Deng, Manman, Deng, Suqi, Li, Peng, Xu, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556349/ https://www.ncbi.nlm.nih.gov/pubmed/28814980 http://dx.doi.org/10.1186/s13148-017-0377-8

Ejemplares similares

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
por: Xu, Li, et al.
Publicado: (2020)

DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progression
por: Lagunas‐Rangel, Francisco Alejandro
Publicado: (2022)

Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
por: Zhong, Mengya, et al.
Publicado: (2021)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients
por: Liu, Fangshu, et al.
Publicado: (2023)

Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways
por: Chen, Qinwei, et al.
Publicado: (2022)

Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1α pathway and generation of reactive oxygen species
por: Zhang, Hongyu, et al.
Publicado: (2017)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients
por: Kassem, Neemat M, et al.
Publicado: (2019)

Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma
por: Annovazzi, Laura, et al.
Publicado: (2017)

Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO–positive acute myeloid leukemia
por: Xi, Yang, et al.
Publicado: (2023)

Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway
por: Lin, Liman, et al.
Publicado: (2020)

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
por: Jiang, Xuejie, et al.
Publicado: (2021)

MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib
por: WANG, GUANGYU, et al.
Publicado: (2015)

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
por: Yao, Yushi, et al.
Publicado: (2013)

Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro
por: Li, Zheng, et al.
Publicado: (2022)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels
por: Huang, He, et al.
Publicado: (2019)

Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway
por: Liang, Simin, et al.
Publicado: (2021)

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
por: Wang, Hao, et al.
Publicado: (2020)

Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics
por: Lee, Michelle H., et al.
Publicado: (2019)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
por: Wang, Lixin, et al.
Publicado: (2020)

P518: VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS
por: LI, Zheng, et al.
Publicado: (2023)

Chidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells
por: Jiang, Duanfeng, et al.
Publicado: (2021)

NG2-proteoglycan-dependent contributions of oligodendrocyte progenitors and myeloid cells to myelin damage and repair
por: Kucharova, Karolina, et al.
Publicado: (2015)

PB1729: RETROSPECTIVE STUDY OF MAINTENANCE THERAPY WITH CHIDAMIDE AFTER TRANSPLANTATION FOR PATIENTS WITH HIGH RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Wang, Xueying, et al.
Publicado: (2023)

High expression of neuroguidin increases the sensitivity of acute myeloid leukemia cells to chemotherapeutic drugs
por: Chen, Kejun, et al.
Publicado: (2015)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
por: Li, Jieqing
Publicado: (2023)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells
por: Ding, Yahui, et al.
Publicado: (2016)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
por: Gu, Siyu, et al.
Publicado: (2023)

FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways
por: Wu, Min, et al.
Publicado: (2019)

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups
por: Riva, L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pfkikpgllmm9a2e4e4av9ua5gd